Kaplan-Meier survival analysis among patients treated with intensive blast-reduction strategies. (A) Comparison of OS among patients achieving CR/CRi, cMPN, or SD as overall best response. (B) Comparison of OS by ELN 2022 response criteria; CR/CRi vs NR/R. (C) Comparison of OS among patients with cMPN reclassified to either responders or nonresponders by ELN 2022 criteria. (D) Landmark Kaplan-Meier survival analysis comparing patients under age 71 who underwent HCT and patients who achieved CR/CRi or cMPN by PM criteria after either intensive or nonintensive blast-reduction strategy and survived at least 155 days (median time to HCT) after transformation to AP/BP but who did not undergo HCT.